RNXT logo

RenovoRx, Inc.

RNXT
Healthcare|Biotechnology|US
$1.13
-0.06 (-5.04%)
DCF Value
$0.89
Tangible Book / Share
$0.19
Cash / Share
$0.22
Next Earnings Report
Mar 29, 2027
EPS est. -$0.05 · Revenue est. $1.5M
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest Apr 27, 2026 (424B3). Possible dilution.

Upcoming Data Readouts (2)

Jun 2027
Est. completion
P3Locally Advanced Pancreatic Cancer
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03257033n=190
Sep 2029
Est. completion
Solid Tumors
PumaRx Registry Trial
NCT06805461n=1,000

Recent Press Releases

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
Nov 5, 2026 · GlobeNewsWire
RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
Oct 28, 2026 · GlobeNewsWire
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Oct 22, 2026 · GlobeNewsWire
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
Oct 7, 2026 · GlobeNewsWire
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
Oct 1, 2026 · GlobeNewsWire
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
Sep 2, 2026 · GlobeNewsWire
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
Aug 25, 2026 · GlobeNewsWire
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
Aug 21, 2026 · GlobeNewsWire
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
Aug 20, 2026 · GlobeNewsWire
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
Aug 12, 2026 · GlobeNewsWire

SEC Filings (54)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 5, 202610-QQuarterly reportDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Oct 16, 2026RWDocumentIndex
Aug 20, 20268-KMaterial eventDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Aug 13, 20268-K/AMaterial eventDocumentIndex
Aug 12, 20268-KMaterial eventDocumentIndex
Aug 4, 20268-KMaterial eventDocumentIndex
Jul 2, 20268-KMaterial eventDocumentIndex
Jun 30, 2026S-8Employee stock planDocumentIndex
Jun 30, 20268-KMaterial eventDocumentIndex
May 15, 202610-K/AAnnual reportDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
Apr 30, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 27, 2026EFFECTDocumentIndex
Apr 27, 2026424B3Offering prospectusDocumentIndex
Apr 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Apr 16, 2026S-3Shelf registrationDocumentIndex
Apr 9, 2026DDocumentIndex
Mar 31, 2026S-8Employee stock planDocumentIndex
Mar 30, 20268-KMaterial eventDocumentIndex
Mar 30, 202610-KAnnual reportDocumentIndex
Mar 27, 20268-KMaterial eventDocumentIndex
Mar 23, 20268-KMaterial eventDocumentIndex
Feb 6, 20268-KMaterial eventDocumentIndex
Jan 30, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 2, 20268-KMaterial eventDocumentIndex
Nov 14, 20258-KMaterial eventDocumentIndex
Nov 14, 2025424B5Offering prospectusDocumentIndex
Nov 14, 2025S-3Shelf registrationDocumentIndex
Nov 13, 20258-KMaterial eventDocumentIndex
Nov 13, 202510-QQuarterly reportDocumentIndex
Nov 13, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 10, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 20258-KMaterial eventDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 202510-QQuarterly reportDocumentIndex
Jun 27, 2025S-8Employee stock planDocumentIndex